University Health Network

Narendra Kumar B Patel

Heinz W Pauls

Sze-Wan Li

Yong Liu

Peter Brent Sampson

Louise G Edwards

Radoslaw Laufer

Bryan T Forrest

Miklos Feher

Grace Ng

Yunhui Lang

Graham Cumming

Guohua Pan

Donald E Awrey

Sze-Wan Ll

Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X; X, and Xis S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I). 

HPK1 inhibitors and methods of using same

The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. 

Pyrazolopyrimidine compounds

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Kinase inhibitors and method of treating cancer with same

Kinase inhibitors and method of treating cancer

The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. 

The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. 

The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein. 

Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2&#x2032;-ones

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells. 

Indazole compounds as kinase inhibitors and method of treating cancer with same

The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Growing community of inventors

Brampton, Canada

Narendra Kumar B Patel